• Solid revenue growth of 33.7% to $628.0m
• Improved operating EBITDA margin of 20.1%
• Capitol merger synergies materially above expectation; now expecting $14.0m annualised

Integral Diagnostics Ltd reported solid financial results for FY25, with revenue growing 33.7% to $628.0m (including ~6-months contribution from Capitol post-merger) and 6.7% growth on an IDX standalone basis. Operating EBITDA increased by 38.3% to $126.5m, with the operating EBITDA margin improving to 20.1%. The company also exceeded its initial expectations for Capitol merger synergies, now expecting $14.0m in annualised synergies, with $7.0m realised in FY25. The company's balance sheet remains strong, with net debt/pro forma EBITDA ratio of 2.6x at 30 June 2025 (2.4x including pro forma annualised synergies). The company continues to focus on driving organic growth, operational efficiencies, and evaluating incremental greenfield and inorganic growth initiatives. Key operational highlights include the expansion of the IDXt teleradiology platform, the opening of five new greenfield clinics, and delivering strong patient satisfaction with an average NPS of +82 in Australia.

Integral Diagnostics expects continued strong revenue growth and further margin expansion, driven by industry tailwinds such as MRI de-regulation, the National Lung Cancer Screening Program, and the GP Bulk Billing Practice Incentive Program. The company expects to realise at least $14.0m in annualised synergies from the Capitol merger.

Integral Diagnostics remains focused on driving organic growth, operational efficiencies, and evaluating incremental greenfield and inorganic growth initiatives. The company is well-positioned to capitalize on industry tailwinds and further strengthen its market-leading position.